Senores Pharmaceuticals Limited has informed the Exchange regarding the media release in relation to the Audited Consolidated and Standalone financial results of the Company for the quarter and financial year ended March 31, 2026

Senores Pharmaceuticals reported exceptional FY26 results with total income of Rs. 664 Crores, up 65% year-on-year. EBITDA more than doubled to Rs. 200 Crores (up 114%) and PAT surged 108% to Rs. 122 Crores. Q4 performance was equally strong with total income at Rs. 190 Crores (up 66%). The Regulated Markets segment drove growth with revenue nearly doubling to Rs. 224 Crores, while the Branded Generics business grew 385% to Rs. 8.2 Crores. The company now has 51 approved ANDAs (up from 26), with 30 yet to be commercialized and 27 more under development. Cash flow from operations improved significantly to Rs. 75 Crores. Strategic moves include the acquisition of Apnar Pharmaceuticals (Phase 1 complete) and formation of a 70% joint venture Amerisyn to enter the U.S. federal/government procurement market.